KR101757502B1 - 트리시클릭 화합물 및 이를 함유하는 ｐｂｋ 저해제 - Google Patents
트리시클릭 화합물 및 이를 함유하는 ｐｂｋ 저해제 Download PDFInfo
- Publication number
- KR101757502B1 KR101757502B1 KR1020127027125A KR20127027125A KR101757502B1 KR 101757502 B1 KR101757502 B1 KR 101757502B1 KR 1020127027125 A KR1020127027125 A KR 1020127027125A KR 20127027125 A KR20127027125 A KR 20127027125A KR 101757502 B1 KR101757502 B1 KR 101757502B1
- Authority
- KR
- South Korea
- Prior art keywords
- quinolin
- phenyl
- hydroxy
- methoxy
- dihydrothieno
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*c(cc(-c1c(C(N2)=O)[s]cc1)c2c1F)c1I Chemical compound C*c(cc(-c1c(C(N2)=O)[s]cc1)c2c1F)c1I 0.000 description 30
- WZCJBZGZBJHYAC-UHFFFAOYSA-N CC(C)(C)OC(NCC(C)(C)c(cc1)ccc1-c(c(OC)c1)c(-c2c(C(N3)=O)[s]cc2)c3c1[Cl-])=O Chemical compound CC(C)(C)OC(NCC(C)(C)c(cc1)ccc1-c(c(OC)c1)c(-c2c(C(N3)=O)[s]cc2)c3c1[Cl-])=O WZCJBZGZBJHYAC-UHFFFAOYSA-N 0.000 description 1
- IVQHYUPLQLTXGR-UHFFFAOYSA-N CC(C)(C)OC(NCC(C)(C)c(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1OC)=O Chemical compound CC(C)(C)OC(NCC(C)(C)c(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1OC)=O IVQHYUPLQLTXGR-UHFFFAOYSA-N 0.000 description 1
- YGCKOQORTKAJQG-BHHNPLSZSA-N CC(CNC(OC(C)(C)C)=O)/C(/C=C\C(c1c2C3C=CSC33)=[O](C)c1ccc2NC3=O)=C(/C)\Cl Chemical compound CC(CNC(OC(C)(C)C)=O)/C(/C=C\C(c1c2C3C=CSC33)=[O](C)c1ccc2NC3=O)=C(/C)\Cl YGCKOQORTKAJQG-BHHNPLSZSA-N 0.000 description 1
- QXFDADZGWGFDCD-UHFFFAOYSA-N CC(c(cc1)ccc1-c1c(-c2c(C(N3C)=O)[s]cc2)c3ccc1O)O Chemical compound CC(c(cc1)ccc1-c1c(-c2c(C(N3C)=O)[s]cc2)c3ccc1O)O QXFDADZGWGFDCD-UHFFFAOYSA-N 0.000 description 1
- MCRKEQBHYKJSTI-UHFFFAOYSA-N CCC(CNC(OC(C)(C)C)=O)c(cc1)ccc1-c(c(-c1c2[s]cc1)c(c(Cl)c1)NC2=O)c1OC Chemical compound CCC(CNC(OC(C)(C)C)=O)c(cc1)ccc1-c(c(-c1c2[s]cc1)c(c(Cl)c1)NC2=O)c1OC MCRKEQBHYKJSTI-UHFFFAOYSA-N 0.000 description 1
- GOUVVCROOHNURG-UHFFFAOYSA-N CCCC(c(cc1)ccc1-c(c(-c1c2[s]cc1)c(cc1)NC2=O)c1OC)N Chemical compound CCCC(c(cc1)ccc1-c(c(-c1c2[s]cc1)c(cc1)NC2=O)c1OC)N GOUVVCROOHNURG-UHFFFAOYSA-N 0.000 description 1
- PYAQOJGSACTWFT-UHFFFAOYSA-N CCCc(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1[O]=C Chemical compound CCCc(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1[O]=C PYAQOJGSACTWFT-UHFFFAOYSA-N 0.000 description 1
- MRVJVBFWGBVULO-LBPRGKRZSA-N CC[C@H](C)c(c(F)c1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3c(C)cc1OC Chemical compound CC[C@H](C)c(c(F)c1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3c(C)cc1OC MRVJVBFWGBVULO-LBPRGKRZSA-N 0.000 description 1
- BNHUWXPVFMZGMF-UHFFFAOYSA-O COCC[NH2+]S(c(cc1)ccc1O)(=O)=O Chemical compound COCC[NH2+]S(c(cc1)ccc1O)(=O)=O BNHUWXPVFMZGMF-UHFFFAOYSA-O 0.000 description 1
- TUZWMLMIACBAHN-UHFFFAOYSA-N COc(c(-c1ccc(CCC=C)cc1)c1-c2c3[s]cc2)ccc1NC3=O Chemical compound COc(c(-c1ccc(CCC=C)cc1)c1-c2c3[s]cc2)ccc1NC3=O TUZWMLMIACBAHN-UHFFFAOYSA-N 0.000 description 1
- YOVKJYDIJCCSOV-LBPRGKRZSA-N C[C@@H](CNC)c(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1O Chemical compound C[C@@H](CNC)c(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1O YOVKJYDIJCCSOV-LBPRGKRZSA-N 0.000 description 1
- HGROMQOIVPWIQV-ZETCQYMHSA-N C[C@@H](COC)c(ccc(Br)c1)c1F Chemical compound C[C@@H](COC)c(ccc(Br)c1)c1F HGROMQOIVPWIQV-ZETCQYMHSA-N 0.000 description 1
- FUDNMMTWIWHXSF-UHFFFAOYSA-N C[N](C)(C)Cc(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1O Chemical compound C[N](C)(C)Cc(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1O FUDNMMTWIWHXSF-UHFFFAOYSA-N 0.000 description 1
- YDYMCJHNSSTDOR-UHFFFAOYSA-N C[N](c(cc1)c(-c2c3[s]cc2)c(-c(cc2)ccc2NS(C)(=O)=O)c1O)(C3=O)#C Chemical compound C[N](c(cc1)c(-c2c3[s]cc2)c(-c(cc2)ccc2NS(C)(=O)=O)c1O)(C3=O)#C YDYMCJHNSSTDOR-UHFFFAOYSA-N 0.000 description 1
- PRLYORQJMCNPDP-UHFFFAOYSA-N NCc(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1O Chemical compound NCc(cc1)ccc1-c1c(-c2c(C(N3)=O)[s]cc2)c3ccc1O PRLYORQJMCNPDP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D519/02—Ergot alkaloids of the cyclic peptide type
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31860610P | 2010-03-29 | 2010-03-29 | |
| US61/318,606 | 2010-03-29 | ||
| PCT/US2011/030278 WO2011123419A1 (en) | 2010-03-29 | 2011-03-29 | Trycyclic compounds and pbk inhibitors containing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20130020666A KR20130020666A (ko) | 2013-02-27 |
| KR101757502B1 true KR101757502B1 (ko) | 2017-07-12 |
Family
ID=44712585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127027125A Expired - Fee Related KR101757502B1 (ko) | 2010-03-29 | 2011-03-29 | 트리시클릭 화합물 및 이를 함유하는 ｐｂｋ 저해제 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8962648B2 (enExample) |
| EP (1) | EP2552206B1 (enExample) |
| JP (1) | JP5849302B2 (enExample) |
| KR (1) | KR101757502B1 (enExample) |
| CN (1) | CN102917590B (enExample) |
| AU (1) | AU2011235319B2 (enExample) |
| BR (1) | BR112012023836B1 (enExample) |
| CA (1) | CA2792941C (enExample) |
| DK (1) | DK2552206T3 (enExample) |
| ES (1) | ES2547571T3 (enExample) |
| IL (1) | IL222080B (enExample) |
| MX (1) | MX2012011412A (enExample) |
| SG (1) | SG184376A1 (enExample) |
| TW (1) | TWI503323B (enExample) |
| WO (1) | WO2011123419A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT201800643T1 (it) * | 2013-12-24 | 2019-01-11 | Bristol Myers Squibb Co | Composti triciclici come agenti anticancro |
| TWI557011B (zh) | 2015-05-25 | 2016-11-11 | 可影像處理的自行車錶裝置 | |
| US10464896B2 (en) | 2015-06-11 | 2019-11-05 | Basilea Pharmaceutica International AG | Efflux-pump inhibitors and therapeutic uses thereof |
| GB201617758D0 (en) | 2016-10-20 | 2016-12-07 | Almac Discovery Limited | Pharmaceutical compounds |
| CN108341774B (zh) * | 2017-01-25 | 2022-07-19 | 首药控股(北京)股份有限公司 | 取代的喹啉酮类抑制剂 |
| MX2019012153A (es) | 2017-04-10 | 2019-11-21 | Bayer Ag | N-ariletil-2-arilquinolina -4-carboxamidas sustituidas y su uso. |
| US12024715B2 (en) | 2017-11-07 | 2024-07-02 | Temple University-Of The Commonwealth System Of Higher Education | Compositions and methods for improved T cells |
| CN111099941B (zh) * | 2018-10-26 | 2022-10-18 | 中国科学院上海有机化学研究所 | 一种烷基腈类化合物的制备方法 |
| TW202300150A (zh) * | 2021-03-18 | 2023-01-01 | 美商薛定諤公司 | 環狀化合物及其使用方法 |
| CN117120447A (zh) * | 2021-03-18 | 2023-11-24 | 薛定谔公司 | 环状化合物和其使用方法 |
| WO2024008113A1 (zh) * | 2022-07-07 | 2024-01-11 | 深圳微芯生物科技股份有限公司 | 一种甲酰胺取代的杂三环类衍生物、其制备方法及其应用 |
| WO2024097228A1 (en) * | 2022-10-31 | 2024-05-10 | Meliora Therapeutics, Inc. | Compounds targeting cdk11 and methods of using the same |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004026864A1 (en) * | 2002-09-17 | 2004-04-01 | Warner-Lambert Company Llc | Heterocyclic substituted piperazines for the treatment of schizophrenia |
| WO2008028168A2 (en) | 2006-09-01 | 2008-03-06 | Cylene Pharmaceuticals, Inc. | Serine-threonine protein kinase and parp modulators |
| US20090239859A1 (en) * | 2008-02-29 | 2009-09-24 | Chua Peter C | Protein kinase modulators |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5377096A (en) * | 1976-12-17 | 1978-07-08 | Teijin Ltd | Preparation of thieno 2,3-c quinolin-4(5h)-one-7-acetic acids |
| FR2636063B1 (fr) * | 1988-09-05 | 1993-04-30 | Centre Nat Rech Scient | Composes phenylpyrroliques utiles en tant que medicaments, leur preparation et leur application |
| DE19806348A1 (de) * | 1998-02-12 | 1999-08-19 | Schering Ag | 3,4-Dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln |
| US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
| US6638929B2 (en) | 1999-12-29 | 2003-10-28 | Wyeth | Tricyclic protein kinase inhibitors |
| WO2001047892A1 (en) * | 1999-12-29 | 2001-07-05 | Wyeth | Tricyclic protein kinase inhibitors |
| DE10242106A1 (de) | 2002-09-11 | 2004-04-15 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Phosphorgruppenhaltige Carbonsäurederivate mit organisch polymerisierbaren Gruppen |
| AU2003301439A1 (en) * | 2002-10-16 | 2004-05-04 | Gilead Sciences, Inc. | Pre-organized tricyclic integrase inhibitor compounds |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| WO2009010804A1 (en) * | 2007-07-19 | 2009-01-22 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Macrocyclic compounds as antiviral agents |
-
2011
- 2011-03-28 TW TW100110555A patent/TWI503323B/zh not_active IP Right Cessation
- 2011-03-29 MX MX2012011412A patent/MX2012011412A/es active IP Right Grant
- 2011-03-29 ES ES11763307.3T patent/ES2547571T3/es active Active
- 2011-03-29 WO PCT/US2011/030278 patent/WO2011123419A1/en not_active Ceased
- 2011-03-29 CA CA2792941A patent/CA2792941C/en active Active
- 2011-03-29 CN CN201180026805.8A patent/CN102917590B/zh active Active
- 2011-03-29 DK DK11763307.3T patent/DK2552206T3/en active
- 2011-03-29 AU AU2011235319A patent/AU2011235319B2/en not_active Ceased
- 2011-03-29 JP JP2013502740A patent/JP5849302B2/ja active Active
- 2011-03-29 EP EP11763307.3A patent/EP2552206B1/en active Active
- 2011-03-29 KR KR1020127027125A patent/KR101757502B1/ko not_active Expired - Fee Related
- 2011-03-29 BR BR112012023836-1A patent/BR112012023836B1/pt not_active IP Right Cessation
- 2011-03-29 SG SG2012072807A patent/SG184376A1/en unknown
- 2011-03-29 US US13/202,544 patent/US8962648B2/en active Active
-
2012
- 2012-09-23 IL IL222080A patent/IL222080B/en active IP Right Grant
-
2014
- 2014-12-09 US US14/565,047 patent/US9453025B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004026864A1 (en) * | 2002-09-17 | 2004-04-01 | Warner-Lambert Company Llc | Heterocyclic substituted piperazines for the treatment of schizophrenia |
| WO2008028168A2 (en) | 2006-09-01 | 2008-03-06 | Cylene Pharmaceuticals, Inc. | Serine-threonine protein kinase and parp modulators |
| US20090239859A1 (en) * | 2008-02-29 | 2009-09-24 | Chua Peter C | Protein kinase modulators |
Non-Patent Citations (1)
| Title |
|---|
| Tetrahedron Letters, 2009, 50(27), 3829-3832* |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2552206B1 (en) | 2015-07-22 |
| HK1179114A1 (en) | 2013-09-27 |
| SG184376A1 (en) | 2012-11-29 |
| JP2013523749A (ja) | 2013-06-17 |
| CN102917590B (zh) | 2016-02-17 |
| CN102917590A (zh) | 2013-02-06 |
| US20150183799A1 (en) | 2015-07-02 |
| TW201136939A (en) | 2011-11-01 |
| EP2552206A4 (en) | 2013-08-14 |
| CA2792941C (en) | 2017-09-12 |
| WO2011123419A1 (en) | 2011-10-06 |
| MX2012011412A (es) | 2013-02-07 |
| IL222080B (en) | 2018-05-31 |
| RU2012145855A (ru) | 2014-05-10 |
| US20130178459A1 (en) | 2013-07-11 |
| TWI503323B (zh) | 2015-10-11 |
| KR20130020666A (ko) | 2013-02-27 |
| AU2011235319B2 (en) | 2016-07-14 |
| ES2547571T3 (es) | 2015-10-07 |
| CA2792941A1 (en) | 2011-10-06 |
| DK2552206T3 (en) | 2015-09-28 |
| US9453025B2 (en) | 2016-09-27 |
| EP2552206A1 (en) | 2013-02-06 |
| JP5849302B2 (ja) | 2016-01-27 |
| BR112012023836A2 (pt) | 2015-09-22 |
| AU2011235319A1 (en) | 2012-10-11 |
| BR112012023836B1 (pt) | 2022-02-01 |
| US8962648B2 (en) | 2015-02-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101757502B1 (ko) | 트리시클릭 화합물 및 이를 함유하는 ｐｂｋ 저해제 | |
| AU2019201352B2 (en) | Bromodomain inhibitors | |
| TWI891649B (zh) | 作為cd38抑制劑之雜雙環醯胺 | |
| AU2009251083B2 (en) | Thienopyridine and furopyridine kinase inhibitors | |
| CN102725296B (zh) | 对蛋白激酶有抑制活性的噻吩并[3,2-d]嘧啶衍生物 | |
| TW201446758A (zh) | 作爲β－分泌酶抑制劑的全氟化５，６－二氫－４Ｈ－１，３－□－２－胺化合物及其用途 | |
| CA2759500A1 (en) | Thieno [2,3-b]pyridine derivatives as viral replication inhibitors | |
| CA2933480A1 (en) | Inhibitors of lysine specific demethylase-1 | |
| KR20070051876A (ko) | Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달 억제제 | |
| CN120641397A (zh) | 稠合吡咯基磺酰胺化合物 | |
| CA2623228A1 (en) | Thieno[2,3-b]pyridine-5-carbonitriles as protein kinase inhibitors | |
| US5977132A (en) | Prolactin production inhibitory agent | |
| JP2022507858A (ja) | Ｉｒａｋ４阻害剤としての新規な三環式化合物 | |
| RU2574398C2 (ru) | ПРОИЗВОДНЫЕ ТИЕНО[2,3-с]ХИНОЛИНА-4-ОНА, ПОЛЕЗНЫЕ ПРИ ЛЕЧЕНИИ РВК-ЗАВИСИМОГО ЗАБОЛЕВАНИЯ | |
| TW202529739A (zh) | Parg之抑制劑 | |
| HK1179114B (en) | Tricyclic compounds and pbk inhibitors containing the same | |
| AU2010247366B2 (en) | Thieno [2, 3-b] pyridine derivatives as viral replication inhibitors | |
| JPH09216823A (ja) | プロラクチン産生抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 4 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 5 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 6 |
|
| PR1001 | Payment of annual fee |
St.27 status event code: A-4-4-U10-U11-oth-PR1001 Fee payment year number: 7 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20240707 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20240707 |